Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk by Anticevic, A. et al.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2015
Association of Thalamic Dysconnectivity and
Conversion to Psychosis in Youth and Young
Adults at Elevated Clinical Risk
A. Anticevic
K. Haut
J. D. Murray
G. Repovs
B. Goodyear
See next page for additional authors
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Psychiatry Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.
Recommended Citation
Anticevic A, Haut K, Murray J, Repovs G, Goodyear B, Cadenhead K, Mirzakhanian H, Cornblatt B, Olvet D, Cannon T, . Association
of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk. . 2015 Jan 01;
72(9):Article 775 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/775. Free full text article.
Authors
A. Anticevic, K. Haut, J. D. Murray, G. Repovs, B. Goodyear, K. S. Cadenhead, H. Mirzakhanian, B. A.
Cornblatt, D. Olvet, T. D. Cannon, and +16 additional authors
This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/775
Association of Thalamic Dysconnectivity and Conversion to 
Psychosis in Youth and Young Adults at Elevated Clinical Risk
Alan Anticevic, PhD, Kristen Haut, PhD, John D. Murray, PhD, Grega Repovs, PhD, 
Genevieve J. Yang, BS, Caroline Diehl, BS, Sarah C. McEwen, PhD, Carrie E. Bearden, PhD, 
Jean Addington, PhD, Bradley Goodyear, PhD, Kristin S. Cadenhead, MD, Heline 
Mirzakhanian, PhD, Barbara A. Cornblatt, PhD, MBA, Doreen Olvet, PhD, Daniel H. 
Mathalon, MD, PhD, Thomas H. McGlashan, MD, Diana O. Perkins, MD, Aysenil Belger, 
PhD, Larry J. Seidman, PhD, Ming T. Tsuang, MD, PhD, DSc, Theo G. M. van Erp, PhD, 
Elaine F Walker, PhD, Stephan Hamann, PhD, Scott W Woods, MD, Maolin Qiu, PhD, and 
Tyrone D. Cannon, PhD
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 
(Anticevic, Yang, Diehl, McGlashan, Woods, Cannon); National Institute of Alcohol Abuse and 
Alcoholism Center for the Translational Neuroscience of Alcoholism, New Haven, Connecticut 
(Anticevic); Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven 
(Anticevic, Yang); Department of Psychology, Yale University, New Haven, Connecticut (Anticevic, 
Haut, Diehl, Cannon); Interdepartmental Neuroscience Program, Yale University, New Haven, 
Connecticut (Anticevic, Yang); Center for Neural Science, New York University, New York 
(Murray); Department of Psychology, University of Ljubljana, Ljubljana, Slovenia (Repovs); 
Departments of Psychiatry and Biobehavioral Sciences and Psychology, University of California, 
Los Angeles (McEwen, Bearden); Department of Psychiatry, University of Calgary, Calgary, 
Alberta, Canada (Addington, Goodyear); Department of Psychiatry, University of California, San 
Diego, La Jolla (Cadenhead, Mirzakhanian, Tsuang); Department of Psychiatry, Zucker Hillside 
Hospital, Glen Oaks, New York (Cornblatt, Olvet); Department of Psychiatry, University of 
California, San Francisco (Mathalon); Department of Psychiatry, University of North Carolina, 
Chapel Hill (Perkins, Belger); Department of Psychiatry, Beth Israel Deaconess Medical Center, 
Corresponding Author: Alan Anticevic, PhD, Department of Psychiatry, Yale University, 34 Park St, New Haven, CT 06519 (; 
Email: alan.anticevic@yale.edu) 
Author Contributions: Dr Anticevic had full access to all the data in the study and takes responsibility for the integrity of the data 
and the accuracy of the data analysis. Drs Anticevic and Haut contributed equally to this work.
Study concept and design: Anticevic, Haut, Murray, Addington, Cadenhead, McGlashan, Perkins, Belger, Tsuang, van Erp, Walker, 
Cannon.
Acquisition, analysis, or interpretation of data: Anticevic, Haut, Repovs, Yang, Diehl, McEwen, Bearden, Goodyear, Mirzakhanian, 
Cornblatt, Olvet, Mathalon, McGlashan, Perkins, Belger, Seidman, van Erp, Walker, Hamann, Woods, Qiu, Cannon.
Drafting of the manuscript: Anticevic, Haut, Mathalon, McGlashan, Seidman, Cannon.
Critical revision of the manuscript for important intellectual content: Anticevic, Murray, Repovs, Yang, Diehl, McEwen, Bearden, 
Addington, Goodyear, Cadenhead, Mirzakhanian, Cornblatt, Olvet, Mathalon, McGlashan, Perkins, Belger, Seidman, Tsuang, van 
Erp, Walker, Hamann, Woods, Qiu, Cannon.
Statistical analysis: Anticevic, Haut, Repovs, Mathalon, Qiu, Cannon.
Obtained funding: Bearden, Addington, Cadenhead, Mirzakhanian, Cornblatt, McGlashan, Perkins, Belger, Seidman, Walker, Cannon.
Administrative, technical, or material support: Haut, McEwen, Addington, Goodyear, Cadenhead, Mirzakhanian, McGlashan, Perkins, 
van Erp, Walker, Qiu.
Study supervision: Anticevic, Bearden, Cadenhead, McGlashan, Tsuang, van Erp, Hamann, Cannon.
Additional Contributions: Michael Cole, PhD, and Heidi Thermenos, PhD, assisted with this article.
Conflict of Interest Disclosures: None reported.
HHS Public Access
Author manuscript
JAMA Psychiatry. Author manuscript; available in PMC 2016 June 03.
Published in final edited form as:
JAMA Psychiatry. 2015 September ; 72(9): 882–891. doi:10.1001/jamapsychiatry.2015.0566.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Boston, Massachusetts (Seidman); Massachusetts General Hospital, Boston (Seidman); 
Department of Psychiatry, Harvard Medical School, and Massachusetts Mental Health Center 
Public Psychiatry Division, Beth Israel Deaconess Medical Center, Boston (Seidman); 
Department of Psychiatry and Human Behavior, University of California, Irvine (van Erp); 
Departments of Psychology and Radiology, Emory University, Atlanta, Georgia (Walker, Hamann); 
Department of Diagnostic Radiology and Magnetic Resonance Research Center, Yale University, 
New Haven, Connecticut (Qiu)
Abstract
IMPORTANCE—Severe neuropsychiatric conditions, such as schizophrenia, affect distributed 
neural computations. One candidate system profoundly altered in chronic schizophrenia involves 
the thalamocortical networks. It is widely acknowledged that schizophrenia is a 
neurodevelopmental disorder that likely affects the brain before onset of clinical symptoms. 
However, no investigation has tested whether thalamocortical connectivity is altered in individuals 
at risk for psychosis or whether this pattern is more severe in individuals who later develop full-
blown illness.
OBJECTIVES—To determine whether baseline thalamocortical connectivity differs between 
individuals at clinical high risk for psychosis and healthy controls, whether this pattern is more 
severe in those who later convert to full-blown illness, and whether magnitude of thalamocortical 
dysconnectivity is associated with baseline prodromal symptom severity.
DESIGN, SETTING, AND PARTICIPANTS—In this multicenter, 2-year follow-up, case-
control study, we examined 397 participants aged 12–35 years of age (243 individuals at clinical 
high risk of psychosis, of whom 21 converted to full-blown illness, and 154 healthy controls). The 
baseline scan dates were January 15, 2010, to April 30, 2012.
MAIN OUTCOMES AND MEASURES—Whole-brain thalamic functional connectivity maps 
were generated using individuals’ anatomically defined thalamic seeds, measured using resting-
state functional connectivity magnetic resonance imaging.
RESULTS—Using baseline magnetic resonance images, we identified thalamocortical 
dysconnectivity in the 243 individuals at clinical high risk for psychosis, which was particularly 
pronounced in the 21 participants who converted to full-blown illness. The pattern involved 
widespread hypoconnectivity between the thalamus and prefrontal and cerebellar areas, which was 
more prominent in those who converted to full-blown illness (t173 = 3.77, P < .001, Hedge g = 
0.88). Conversely, there was marked thalamic hyperconnectivity with sensory motor areas, again 
most pronounced in those who converted to full-blown illness (t173 = 2.85, P < .001, Hedge g = 
0.66). Both patterns were significantly correlated with concurrent prodromal symptom severity (r 
= 0.27, P < 3.6 × 10−8, Spearman ρ = 0.27, P < 4.75 × 10−5, 2-tailed).
CONCLUSIONS AND RELEVANCE—Thalamic dysconnectivity, resembling that seen in 
schizophrenia, was evident in individuals at clinical high risk for psychosis and more prominently 
in those who later converted to psychosis. Dysconnectivity correlated with symptom severity, 
supporting the idea that thalamic connectivity may have prognostic implications for risk of 
conversion to full-blown illness.
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Schizophrenia is characterized as a neurodevelopmental disorder1 of distributed brain 
dysconnectivity,2 emerging from complex biological alterations that affect large-scale neural 
systems.3 Its symptoms are correspondingly pervasive,4 leading to lifelong disability for 
most patients5 and profound economic consequences. Understanding neural disturbances in 
schizophrenia constitutes a critical research goal that necessitates identification of 
pathophysiologic mechanisms and biomarkers that aid risk prediction. Growing 
sophistication in non-invasive neuroimaging offers away to characterize large-scale neural 
system disturbances in psychiatric illness6–8 by studying low-frequency fluctuations in the 
blood oxygenation level–dependent (BOLD) signal at rest7 (ie, via resting-state functional 
connectivity magnetic resonance imaging [rs-fcMRI]). This technique is increasingly 
applied to the study of neuropsychiatric conditions given its brief acquisition time, cost-
effectiveness, and reproducibility6,9 based on the hypothesis that conditions such as 
schizophrenia are brain disorders that affect exchange of information across large-scale 
neural networks.
One such neural system, repeatedly implicated in schizophrenia,10–12 involves 
thalamocortical loops13 through which most neural computations flow. Thalamocortical 
systems have been studied extensively in humans using noninvasive neuroimaging.14 Both 
rs-fcMRI14 and structural diffusion studies in humans15,16 revealed that the thalamus is 
organized into parallel pathways that form information routes with the neocortex. This 
property makes the thalamus an ideal starting point and a possible lens into large-scale 
neural system disruptions in schizophrenia.12,17
Indeed, several groups have recently reported disrupted thalamocortical functional 
connectivity in chronic schizophrenia.10–12 However, schizophrenia is a neurodevelopmental 
illness associated with brain abnormalities that likely occur before onset of all clinical 
symptoms.18 Currently, it is unknown whether thalamocortical dysconnectivity emerges 
exclusively in association with chronic illness or whether high clinical risk (CHR) and 
subsequent longitudinal conversion to full-blown illness (CHR-C), as opposed to 
nonconversion (CHR-NC), are also associated with functional thalamocortical disruptions. It 
is vital to address this question for 3 reasons: (1) to elucidate how incipient pathophysiologic 
stages of putative schizophrenia affect large-scale neural systems before full-blown 
symptoms emerge; (2) to establish whether disruptions in thalamocortical connectivity could 
provide viable neural markers associated with clinical risk before conversion; and (3) to 
extend recent discoveries while bypassing typical confounds associated with chronic illness 
(eg, years of medication exposure).
In this study, we examined resting-state thalamocortical connectivity in the North American 
Prodromal Longitudinal Study (NAPLS) clinical high-risk sample. After obtaining baseline 
images, we longitudinally studied 243 CHR patients (21 CHR-C patients and 222 CHR-NC 
patients) and 154 healthy controls who were demographically similar to the clinical group. 
We tested the following 3 questions: (1) “Is CHR associated with thalamocortical 
dysconnectivity?” (2) “Is thalamocortical dysconnectivity more severe in CHR-C compared 
with CHR-NC patients?” and (3) “Is thalamocortical dysconnectivity associated with 
severity of psychotic symptoms at baseline?”
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Methods
Participants
Our final sample included 243 CHR individuals (21 in the CHR-C group and 222 in the 
CHR-NC group) and 154 controls. All participants were recruited as part of the NAPLS 2 
cohort19 and underwent rs-fcMRI at their baseline evaluations (eTable 1 in the Supplement). 
The study protocol and consent form were reviewed and approved by the institutional review 
boards at each of the 8 participating data collection sites (University of California, Los 
Angeles, Emory University, Harvard Medical School, Zucker Hillside Hospital, University 
of North Carolina, University of California, San Diego, University of Calgary, and Yale 
University). All participants provided written informed consent. All recruitment, symptom 
assessment, and longitudinal evaluation details are presented in eTable 1 in the Supplement.
All participants were between 12–35 years of age with IQ >70, no history of central nervous 
system disorders and no substance dependence in the past 6 months. The CHR sample met 
the Criteria of Prodromal Syndromes (COPS) following assessment with the Structured 
Interview for Prodromal Syndromes (SIPS) by experienced MA/PhD level clinicians. 
Participants were excluded for current or past diagnosis with Axis I psychotic disorders, 
including affective psychoses, as determined by the Structured Clinical Interview for the 
Diagnostic and Statistical Manual of Mental Disorders-IV (SCID). Other co-morbid Axis I 
diagnoses, such as mood or anxiety disorders, were not exclusionary provided they did not 
account for the subject’s prodromal symptoms. There were no significant differences in 
substance use, anxiety, or age between CHR subjects who converted and those who did not. 
HCS were excluded if they met criteria for any prodromal syndrome, current or past 
psychotic disorder, or Cluster A personality disorder. HCS were also excluded for family 
history (first-degree relatives) of any disorder involving psychotic symptoms and for current 
use of psychotropic medication.
Neuroimaging Data Acquisition
Neuroimaging was performed at 8 sites. Five sites (University of California, Los Angeles, 
Emory University, Harvard University, University of North Carolina, and Yale University) 
used Siemens-Trio 3-T scanners (Siemens), 2 sites (Zucker Hillside Hospital and University 
of California, San Diego) used General Electric HDx Signa scanners (General Electric), and 
1 site (University of Calgary) used a General Electric Discovery scanner (General Electric). 
All neuroimaging and functional connectivity analyses followed prior work and best 
practices in the clinical connectivity literature,20,21 with details presented in the eAppendix 
in the Supplement.
Seed-Based Functional Connectivity Analysis Based on Thalamic Anatomy
Our seed-based approach followed a prior study22 using anatomically defined thalamic 
nuclei. In-house Matlab tools23,24 were used to examine thalamus connectivity with all gray 
matter voxels. We computed a seed-based thalamus correlation map by extracting mean time 
series across all voxels in each participant’s bilateral thalamus (anatomically defined through 
Freesurfer-based segmentation25,26). This entire thalamic signal was then correlated with 
each gray matter voxel, and the computed Pearson correlation values were transformed to 
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Fisher z values using a Fisher r-to-z transformation, providing a map for each participant 
that was entered into second-level analyses in which each voxel’s value represented its 
connectivity with the whole thalamus (eAppendix in the Supplement). To examine between-
group differences, all individual-subject maps were entered into appropriate second-level 
tests (either independent samples t-test or 1-way ANOVA with three between-group levels 
[CHR-NC, CHR-C, HCS]), which was computed within FSL’s Randomize tool with 10,000 
permutations. Type I error correction was determined via threshold-free cluster enhancement 
(TFCE) using a P <.01 as the statistical threshold.
Results
Association of Psychosis Risk and Thalamic Dysconnectivity
We tested whether the risk of psychosis was associated with thalamocortical dysconnectivity 
across the 21 participants in the CHR-C group, 222 participants in the CHR-NC group, and 
the 154 participants in the control group (computed via 1-way analysis of variance with one 
between-group factor). We took 2 approaches to testing this hypothesis: (1) at the whole-
brain level without regional constraints (eFigure 1 in the Supplement) and (2) within regions 
known to exhibit robust thalamocortical dysconnectivity in chronic schizophrenia10–12 
(eFigure 2 in the Supplement). Although similar effects were apparent in both cases, the 
whole-brain results did not survive type I error correction (eFigure 1 in the Supplement). 
The a priori constrained analyses, however, revealed robust between-group differences best 
described as increased connectivity between thalamus and bilateral sensory motor cortices 
but decreased connectivity among the thalamus, prefrontal cortex (PFC), and cerebellum, 
similar to prior qualitative and quantitative observations in chronic schizophrenia.10–12 This 
effect was more prominent in CHR-C patients (Figure 1 and Table). To further characterize 
the effects, we extracted the mean thalamic functional connectivity from the identified 
regions of interest, as well as the connectivity distributions across all voxels (Figure 1). 
Results indicated a marked shift for the CHR-C patients across all regions of interest, 
confirmed via formal effect sizes (ie, overall hyperconnectivity: t173 = 3.77, P < .001, Hedge 
g = 0.88;overall hypoconnectivity: t173 = 2.85, P < .001, Hedge g = 0.66).28 Across areas, 
the CHR-NC group was associated with an intermediate level of dysconnectivity between 
the individuals in the CHR-C and control groups.
These results, however, were restricted within the a priori regions previously identified in 
chronic schizophrenia, guaranteeing effects across similar regions. There may be attenuated 
effects elsewhere that do not resemble prior schizophrenia results. To examine this 
possibility, we computed 2 post hoc pairwise comparisons presented at lower thresholds, 
allowing qualitative inspection (eFigure 5 in the Supplement). Results revealed consistent 
patterns of increased connectivity around sensory motor cortices but reductions around PFC, 
striatum, and cerebellum, which were also more prominent in the CHR-C group.
Finally, there is increasing emphasis on processing procedures in rs-fcMRI research because 
certain procedures, specifically, global signal regression (GSR) (eAppendix in the 
Supplement), may complicate between-group comparisons.29 The GSR is associated with 
the removal of a mean brain signal from each voxel’s time series, the magnitude of which 
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may differ among clinical conditions.30 To rule out GSR confounds, we repeated analyses 
without GSR (eFigure 3 and eFigure 4 in the Supplement), which did not alter results.
Patterns of Thalamocortical Dysconnectivity and Shared Disturbances
The present effects highlight 2 dissociable patterns: hyperconnectivity centered on sensory 
motor cortices and reductions in thalamo-prefrontal-cerebellar connectivity. These effects 
may reflect separable alterations.12 Alternatively, as found in chronic schizophrenia,12 these 
findings could constitute shared disturbances whereby individuals with most severe 
thalamic-sensory perturbations also have the greatest thalamo-prefrontal-cerebellar 
dysconnectivity. To test this hypothesis, we correlated the strength of connectivity from 
regions with reduced thalamic connectivity with regions with increased thalamic 
connectivity, explicitly following approaches in our prior work (Figure 2).12
Across all participants, there was a highly significant negative relationship (N = 397, r = 
−0.58, P < 4.1 × 10−38) between the 2 findings, which held for the CHR group (N = 242, r = 
−0.53, P < 1.2 × 10−19): individuals with the most severe thalamic-sensory 
hyperconnectivity had the greatest thalamo-prefrontal-cerebellar hypoconnectivity. This 
pattern indicates that the 2 disruptions represent shared thalamocortical alterations, 
consistent with schizophrenia findings.12
Association Between Baseline Symptoms and Thalamic Dysconnectivity
Next, to provisionally test the clinical significance of thalamic dysconnectivity, we examined 
its association with symptoms. We examined the composite score using the Scale of 
Prodromal Symptoms (SOPS; composite positive symptoms31) for 2 reasons. First, prior 
work12 in chronic schizophrenia identified a significant association between positive 
symptoms and thalamic-sensory-motor hyperconnectivity, providing strong a priori 
predictions. Second, we sought to circumvent stringent type I error correction arising from 
many exploratory comparisons. We correlated symptoms with connectivity measures 
separately for areas with reduced vs increased thalamic connectivity (ie, aggregate signal 
across yellow vs blue foci in Figure 1). We examined this association across all participants 
to remain maximally powered and motivated by a Research Domain Criteria32 strategy 
because low SOPS scores may exist even in the general population (eTable 1 in the 
Supplement). We identified a significant negative correlation between regions with thalamic 
hypoconnectivity and symptoms (r = −0.31, P < 9.54 × 10−10, Spearman ρ = −0.32, P < 1.36 
× 10−9, 2-tailed), which also held when we restricted analyses to those individuals who 
presented with symptoms (r = −0.21, P < .001, Spearman ρ = −0.22, P < .001, 2-tailed) and 
only to CHR patients (r = −0.14, P = .03, Spearman ρ = −0.32, P = .04, 2-tailed; eFigures 6 
and 7 in the Supplement). There was also a significant positive correlation between SOPS 
scores and hyperconnectivity across participants (r = 0.21, P < 4.1 × 10−5, Spearman ρ = 
0.21, P < 4.8 × 10−5 ; Figure 3), which did not survive when we restricted the analysis to 
symptomatic participants or CHR patients (eFigure 7 in the Supplement). To confirm that 
the 2 disturbances are related, we calculated the difference in magnitude of 
hyperconnectivity vs hypoconnectivity for each participant (ie, difference in connectivity for 
yellow vs blue foci in Figure 1). We correlated the magnitude of this connectivity difference 
with symptoms, which also revealed a significant association (r = 0.27, P < 3.6 × 10−8, 
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Spearman ρ = 0.27, P < 4.75 × 10−5, 2-tailed), which held when we restricted analyses to 
those individuals who presented with symptoms (r = 0.17, P < .001, Spearman ρ = 0.14, P 
< .001, 2-tailed) but did not survive when restricted to CHR patients (eFigure 7 in the 
Supplement). Of note, we did not identify a significant association between identified 
thalamic dysconnectivity and SOPS scores at the 2-year follow-up.
Association Between Medication and Thalamic Dysconnectivity
Last, we tested whether identified thalamic dysconnectivity was related to medication dose 
and/or status. We first correlated medication level (calculated via chlorpromazine 
equivalents33) with magnitude of thalamic hyperconnectivity and hypoconnectivity. This 
analysis revealed no significant association, although there were modest trends (thalamic 
hyperconnectivity: r = 0.19, P = .19; thalamic hypoconnectivity: r = −0.2, P = .16; n = 50 
medicated patients). These trends imply that individuals who received higher doses of 
medication had greater thalamocortical dysconnectivity at baseline. Next, we tested whether 
effects differed as a function of medication status (because some individuals were medicated 
even at their baseline scans34) (Figure 4). This analysis revealed that unmedicated patients in 
the CHR-Cgroup (n = 17) exhibited the most profound thalamic-sensory-motor 
hyperconnectivity (Figure 4), which significantly differed from the controls (t169 = 3.7, P < .
001, 2-tailed, Hedge g = 0.81). This effect is the opposite of what one would expect if a 
medication confound were driving thalamic hyperconnectivity because medicated 
individuals had a milder profile. Medicated and unmedicated patients in the CHR-C group 
exhibited thalamic hypoconnectivity of similar magnitude (Figure 4). Again, the 
unmedicated patients in the CHR-C group significantly differed from the controls (t169 = 
2.34, P = .02, 2-tailed, Hedge g = 0.31). These secondary medication analyses rule out the 
possibility that medication is driving the observed patterns.
Discussion
Thalamic circuits feature prominently in theoretical models of schizophrenia17,35 and are 
implicated in empirical schizophrenia studies.10–12 However, patterns of thalamic 
dysconnectivity before full-blown illness conversion remain unknown. To address this 
knowledge gap, we used rs-fcMRI to characterize thalamocortical dysconnectivity in 
association with clinical risk and future conversion to full-blown psychosis. We identified 
patterns consistent with recent discoveries in schizophrenia10–12: increased thalamic 
connectivity with sensory motor cortices but reduced thalamic connectivity with PFC and 
cerebellum, a pattern more prominent in CHR-C patients. Both patterns were modestly 
correlated with symptoms and were observed in unmedicated individuals in the CHR group. 
Results were observed during baseline imaging before psychosis onset, indicating that these 
disturbances predate full-blown illness.
Risk for Psychosis and Thalamocortical Dysconnectivity
Schizophrenia is a neurodevelopmental disorder associated with genetic risk factors.36,37 
However, indicators of its emerging pathophysiologic conditions remain poorly understood, 
with few viable neural markers that predict illness development and subsequent frank onset. 
This lack of at-risk endophenotypes for schizophrenia is compounded by the scarcity of 
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well-established neural markers of chronic illness. The field has made progress in defining 
neural markers of cortical and subcortical dysfunction in schizophrenia through a 
combination of postmortem38–40 and neuroimaging studies examining structure,41 task-
based activation,42–46 and functional and structural connectivity.21,47 This work has been 
enriched by resting-state studies mapping large-scale network disturbances in 
schizophrenia48: during the past year, several groups independently replicated prominent 
thalamocortical disturbances in chronic schizophrenia.10–12 Although promising, this work 
has not addressed 2 vital questions. First, “Are the observed thalamocortical connectivity 
disturbances in part related to long-term medication effects?” Second, from a clinical 
standpoint, “Are these thalamocortical connectivity disturbances an exclusive feature of 
long-standing illness, or do they emerge during early illness stages?” The second question is 
particularly important for identifying neural markers that appear before progression to 
chronic illness.
We found that thalamocortical dysconnectivity was present in the CHR state before full-
blown psychosis. The effects followed previously reported hyperconnectivity with sensory 
motor areas and hypoconnectivity with PFC and cerebellum (note that hyperconnectivity 
with other auditory and visual sensory regions was evident, although these regions did not 
survive more stringent thresholding). Both patterns were more severe for CHR-C patients, 
suggesting pathophysiologic relevance to the pathogenic cascade that culminates in 
psychosis. These effects address the limitations of prior long-term studies: because thalamic 
dysconnectivity in CHR patients closely mirrors effects reported in patients with chronic 
illness and these patterns were observed in unmedicated patients, it is unlikely that these 
alterations are driven by long-term pharmacotherapy. However, our analyses provisionally 
imply that medication may exert a beneficial effect by reducing thalamocortical 
hyperconnectivity.
Follow-up analyses revealed similar effects even at lower statistical thresholds (Figure 2). 
Furthermore, thalamic hyperconnectivity and hypoconnectivity were highly related across 
participants, suggesting a common system-wide disturbance (as reported in chronic 
schizophrenia10–12). Finally, the magnitude of thalamic dysconnectivity in both 
hyperconnected and hypoconnected regions predicted symptoms. The difference in 
magnitude between hyperconnectivity and hypoconnectivity also correlated with symptoms, 
supporting the hypothesis that the 2 effects constitute a shared, system-wide thalamic 
abnormality. By linking thalamic dysconnectivity with symptom levels before illness onset, 
these results raise the question of whether thalamic dysconnectivity relates to genetic risk 
and/or appears in unaffected relatives or whether it only emerges in association with 
symptom expression (because patients in the CHR group were seeking help).
Although this study focused on the thalamus, other groups documented abnormalities across 
striatal and cortical networks during CHR states49 or in patients with chronic illness.9,50–52 
Therefore, thalamocortical dysconnectivity cannot be construed as the only disturbance that 
occurs during this at-risk period. For instance, Fornito and colleagues49 reported changes in 
frontostriatal circuits that were strikingly similar to reported thalamic effects: a prominent 
dorsal-to-ventral gradient of hypoconnectivity to hyperconnectivity between the striatal and 
PFC regions, which correlated with symptoms. Baker and colleagues50 reported functional 
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connectivity disruptions in associative cortices in patients with chronic illness, which may be 
related to abnormal BOLD signal variance in these same associative networks.30 It is unclear 
whether these disparate effects possibly reflect common upstream mechanisms3 (eg, 
disrupted glutamate signaling or microglial alterations) or whether they constitute separable 
abnormalities that emerge at distinct illness stages.53,54 Longitudinal and genetic studies are 
needed to map risk- and disease-related connectivity changes in relation to these emerging 
neuroimaging markers. Such efforts will help disambiguate which markers relate to genetic 
risk, early-course prodromal symptoms, frank illness onset, and, ultimately, chronic illness 
effects, informing therapeutic design for specific illness phases. Finally, although these 
effects are potentially compelling, the relatively small sample of converters limits firm 
conclusions about whether this particular imaging phenotype is a true clinical predictor of 
conversion.
Implications for the Neurobiology of Schizophrenia Onset
Present findings are correlational given the indirect neuroimaging measure (BOLD fcMRI) 
and therefore cannot address upstream causal mechanisms. To map such upstream cellular 
mechanisms, translational research from animal experiments,55 experimental pharmacologic 
neuroimaging studies,56 and computational models can generate mechanistic and testable 
predictions.17,30,57,58 Schizophrenia likely involves alterations in glutamatergic, 
dopaminergic, and inhibitory gamma-aminobutyric acid (GABA) 
neurotransmission.3,38,39,59–62 Theoretical models of the illness repeatedly implicate these 
neurotransmitter systems in thalamo-striatal-cortical circuits, which may contribute to the 
observed alterations. It currently remains unknown which upstream mechanisms and at 
which locus (subcortical or cortical) produce such widespread thalamic dysconnectivity. One 
possibility may involve dysfunction of the N-methyl-D-aspartate glutamate receptor,63 
hypothesized to occur in inhibitory interneurons,38,39,62 which affects the balance of neural 
excitation and inhibition64 in cortical circuits, producing brain-wide disturbances in 
thalamocortical information flow.
Limitations
Although medication effects were largely ruled out, some CHR patients were medicated. 
Thus, we correlated medication levels with magnitude of thalamocortical dysconnectivity, 
which did not reveal significant effects. Furthermore, we compared medicated and 
unmedicated CHR patients: although hypoconnectivity did not vary as a function of 
medication status, the hyperconnectivity profile was actually worse for unmedicated CHR 
patients, suggesting that medication did not drive primary effects. Another concern, present 
in all clinical connectivity studies, relates to head movement. We used careful movement-
censoring methods for all data and used movement (percentage of frames scrubbed) as a 
covariate in the analysis, which did not alter effects (eAppendix in the Supplement). 
Movement levels did not significantly differ between CHR-NC and CHR-C patients (Table), 
increasing confidence that head movement did not drive effects. The data were pooled from 
multiple sites and scanners, introducing possible scanner bias and other site-specific effects 
on cohort recruitment and assessment. To mitigate this concern, we conducted 2 analyses: 
we confirmed that results remained despite using site as a covariate in the reported analysis 
(of note, there was a slight deviation from expected proportions revealed by a χ2 test; eTable 
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2 in the Supplement). Another issue relates to the definition of risk; here, we studied 
individuals who were clinically symptomatic and seeking help and therefore presented with 
clinical elevated risk for psychosis conversion. Consequently, these findings cannot directly 
address whether genetic liability for schizophrenia is associated with the same pattern of 
thalamic dysconnectivity. We observed reported effects within a priori masks exhibiting 
thalamocortical dysconnectivity in our prior work12 but not at the whole-brain level. This 
finding may reflect restricted power because of the relatively smaller CHR-C group but also 
the possibility that the CHR state may be associated with weaker effects relative to the more 
robust patterns found in patients with chronic illness.12 In addition, although starting from 
the entire thalamus may be a well-justified first-pass approach (to remain sensitive to pan-
thalamic disruptions), there may be important discrepancies across thalamic subnuclei that 
the current analysis did not consider.10,65
Conclusions
This study establishes that thalamocortical dysconnectivity is present in CHR states before 
psychosis onset. We found that sensory motor and prefrontal-cerebellar thalamic 
dysconnectivity was more severe in the CHR-C patients. These effects are congruent with 
recent discoveries in patients with chronic illness, suggesting that brain-wide 
thalamocortical dysconnectivity is apparent even during incipient illness stages and may 
provide a sensitive marker for elevated clinical risk of full illness onset.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Regions With Between-Group Differences in Thalamic Connectivity
Significant between-group effects were found for 5 regions of interest (ROIs) after a 1-way 
analysis of variance F test using cluster protection after 10 000 permutations27 (see 
Methods). Results were visualized using surface-based and volume maps. All displayed foci 
revealed significant between-group effects within the thalamocortical masks identified in our 
prior work12 (in which patients with chronic illness exhibited robust thalamocortical 
disruptions; eAppendix and eTables 3 and 4 in the Supplement). Blue and yellow areas 
indicate regions where the F test is driven by a reduction or increase, respectively, in 
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thalamic connectivity in the clinical high risk for psychosis (CHR) groups. Magnitudes (left) 
and distributions (right) across groups for each of the identified regions qualitatively 
illustrate the direction of the effect. Effect sizes (Hedge g [Hg]) reflect the shift for the CHR 
converted to full-blown illness (CHR-C) group relative to controls. For a complete list of 
regions and statistics, see the Table. We used the Hg as a measure of effect size to account 
for differences in sample size between the CHR-C and CHR-nonconversion (CHR-NC) 
groups.28 Error bars indicate ±1 SEM. The histograms are based on the data extracted from 
the F map presented in the surface view panel. We present reduced-threshold pairwise 
effects in the eAppendix in the Supplement. L indicates left; and R, right.
a
 P < .01.
b
 P < .001.
c
 P < .05.
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Figure 2. Association Between Thalamic Hyperconnectivity and Hypoconnectivity Across Study 
Participants
Regions with reduced (blue) and increased (yellow) thalamic connectivity (Figure 1). A 
significant negative association is evident across all participants, collapsing across all 3 
samples (r = −0.58, P < 4.1 × 10−38). Vertical/horizontal green dashed lines mark the zero 
points. Patients with clinical high risk of psychosis (CHR) who converted to full-blown 
illness (CHR-C) had a shift across the zero lines, indicative of weaker prefrontal-cerebellar-
thalamic connectivity but stronger sensory-motor-thalamic connectivity. Patients with CHR 
who did not convert (CHR-NC) had a more intermediate degree of disruption, suggesting a 
gradient (inset arrow for qualitative illustration). Ovals for each group mark the 95%CI. L 
indicates left; and R, right.
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Figure 3. Association Between Prodromal Schizophrenia Symptoms and Thalamic 
Dysconnectivity
Regions showing reduced (blue) and increased (yellow) thalamic connectivity. Significant 
positive association was found between thalamic connectivity across all areas showing 
increased connectivity (yellow regions) and composite positive symptoms on the Scale of 
Prodromal Symptoms (SOPS) across all participants (r = 0.21, P < 4.1 × 10−5, Spearman ρ = 
0.21, P < 4.8 × 10−5). A significant negative association was found between thalamic 
connectivity across all areas showing reduced connectivity (blue regions) and composite 
positive symptoms on the SOPS across all participants (r = −0.31, P < 9.54 × 10−10, 
Spearman ρ = −0.32, P < 1.36 × 10−9, 2-tailed). We computed a difference score between the 
regions showing hyperconnectivity (yellow) and hypoconnectivity (blue). The purpose of 
this calculation was to establish that the total magnitude of connectivity disruptions in either 
direction still relates to psychotic symptoms as opposed to these 2 patterns capturing 
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independent sources of variability. We found a significant association between thalamic 
connectivity difference score and composite positive symptoms on the SOPS across all 
participants (r = 0.27, P < 3.6 × 10−8, Spearman ρ = 0.27, P < 4.75 × 10−5, 2-tailed). For a 
figure presenting clinical high risk (CHR) patients only, see eFigure 7 in the Supplement. 
CHR-C indicates clinical high risk of psychosis converted to full-blown illness; CHR-NC, 
clinical high risk of psychosis not converted to full-blown illness; L indicates left; and R, 
right.
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Figure 4. Thalamic Dysconnectivity as a Function of Medication Status
Regions with reduced (blue) and increased (yellow) thalamic connectivity, driven by the 
clinical high risk of psychosis (CHR) converted to full-blown illness (CHR-C). The 
association between medication status and thalamic hyperconnectivity indicated that CHR-C 
patients who remained unmedicated (CHR-C-UM) exhibited the most severe 
hyperconnectivity, significantly differing from controls (t169 = 3.7, P < .001, 2-tailed, Hedge 
g = 0.81) and CHR patients who did not convert (CHR-NC) without medication (CHR-NC-
UM) (t190 = 2.27, P = .02, 2-tailed, Hedge g = 0.53). However, no significant difference was 
found between medicated (CHR-C-M and CHR-NC-M) and CHR-C-UM and CHR-NC-UM 
patients (t19 = 0.46, P = .76). Again, CHR-C-UM patients exhibited significant reductions in 
thalamic connectivity with prefrontal cortex and cerebellar nodes relative to controls (t169 = 
2.34, P = .02, 2-tailed, Hedge g = 0.31) but not the other clinical groups. We used Hedge g 
as a measure of effect size to account for differences in sample sizes.28 Error bars indicate 
±1 SEM. L indicates left; and R, right.
a
 P < .001.
b
 P < .05.
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